Methodology and results of a long-term, controlled study of the effectiveness of immunosuppressive treatment of multiple sclerosis

  • Peter R. Pocklington
  • Udo Patzold
Conference paper
Part of the Medizinische Informatik, Biometrie und Epidemiologie book series (MEDINFO, volume 28)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. (1).
    Aimard,G., Girard,P.F., Raveau,J.: Sclérose en plaques et processus d’auto-immunisation Traitment par les antimitotiques. Lyon Medical 215, 345–352 (1966)Google Scholar
  2. (2).
    Armitage,P.: Sequential Medical Trials. Oxford, Blackwell Scientific Publications, 1960Google Scholar
  3. (3).
    Brendel,W.,Ring,J., Seifert,J.: Immunosuppressive treatment of multiple sclerosis with ALG and/or thoracic duct drainage. Neurology (Minneap) 25, (1975) 490Google Scholar
  4. (4).
    Canner, P.L.: Monitoring treatment differences in long-term clinical trials. Biometrics 33 (1977) 603–616CrossRefGoogle Scholar
  5. (5).
    Delpech,B., Lichtblau,E.: Etude quantitativ des immunoglobulines G et de l’albumine du liquide cephalorachidien. Clin. chem. Acta 37 (1972) 15–23CrossRefGoogle Scholar
  6. (6).
    Fog,T., Linnemann,E.: The course of multiple sclerosis in 73 cases with computer designed curves. Acta Neurol. Scand.(Suppl.) (1970) 47Google Scholar
  7. (7).
    Frick,E., Angstwurm,H., Strauss,G.: Immunsuppressive Therapie der Multiplen Sklerose. 4. Mitteilung: Behandlungsergebnisse mit Azathioprin und Antilymphocytenglobulin. Munch, med. Wochhenschr. 119 (1977) 1111–1114Google Scholar
  8. (8).
    Gonsette,R.E., Demonty,L., Delmotte,P.: Intensive immunosuppression with cyclophosphamide in multiple sclerosis. J. Neurol. 214 (1977) 173–181CrossRefGoogle Scholar
  9. (9).
    Göpel,W., Benkenstein,H., Benzhaf,M.: Die immunsuppressive Behandlung der Multiplen Sklerose mit Cyclophosphamid und Imuran. Dtsch. Ges.-Wesen 27 (1972) 1955–1961Google Scholar
  10. (10).
    Hommes, O.R., Prick, J.J., Lamers, K.J.B.: Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin. Neurol. Neurosurg. 1 (1975) 59–72CrossRefGoogle Scholar
  11. (11).
    Lance,E.M. et al.: Intensive immunosuppression in patients with dissimated sclerosis. I. Clinical Response. Clin. Exp. Immunol. 21 (1975) 1–12Google Scholar
  12. (12).
    Lhermitte,F. et al.: The frequency of relapse in multiple sclerosis. A study based on 245 cases. Z. Neurol. 205 (1973) 47–59Google Scholar
  13. (13).
    Mertens,H.G.: Therapie der Multiplen Sklerose. In: H.H.Wieck (Ed.), Langzeittherapie neuropsychiatrischer Erkrankungen, Erlangen, Straube (1978)Google Scholar
  14. (14).
    Muller,J., Kreiner,R., Sauermann,W.: Vorlaeufige Erfahrungen mit der Imurek-Behandlung bei Multiple Sklerose. Psychiat. Neurol. med. Psychol., Leipzig 28 (1976) 755–761Google Scholar
  15. (15).
    Oger,J. et al.: Considerations sur une experience de traitment a visee immuno-suppressive dans la sclerose en plaques. In: Schuller,F. (Ed.): Immunopathologie du Systeme nerveuse, Paris, Iserm (1975)Google Scholar
  16. (16).
    Patzold,U., Weinrich,W.: Vorschlag einer neurologischen Befunddokumentation mittels Markierungsbeleg. Nervenarzt 46 (1975) 550–556Google Scholar
  17. (17).
    Patzold,U. et al.: Therapie der Multiplen Sklerose mit Bevamisol und Azathioprin. Vergleich der Wirksamkeit einer ’ immunstimulierenden’ und ’immunsuppressiven’ Behandlung. Nervenarzt 49 (1978) 285–294Google Scholar
  18. (18).
    Pocklington,P.r.: CTIS -Clinical Text Inquiry System. In: Reichertz, P.L. (Ed.): Medizinische Informatik 1975, Berlin, Springer Verlag (1976) 118–123CrossRefGoogle Scholar
  19. (19).
    Pocklington, P.R.: The necessity for, requirements of, and basic design of a General Data Interpretation and Evaluation System. In: Anderson,J., Forsythe,J.M.: Medinfo 74, Amsterdam, North Holland Publishing Co., (1975) 411–418Google Scholar
  20. (20).
    Reichertz,P.l.: Medical School of Hannover Hospital Computer System (Hannover). In: Collen,M.F.(Ed.): Hospital Computer Systems, New York, Wiley (1974) 598–661Google Scholar
  21. (21).
    Ring,J. et al.: Pilot study with antilymphocite globuline in the treatment of multiple sclerosis. Postgrad. Med. J. 52 (Suppl. 5) (1976) 123–128Google Scholar
  22. (22).
    Rosen,J.A.: Prolonged azathioprine treatment of non-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiat. 42 (1979) 338–344CrossRefGoogle Scholar
  23. (23).
    Schumacher,G.A.: Critique of experimantal trials of therapy in multiple sclerosis. Neurology (Minneap.) 24 (1974) 1010–1014CrossRefGoogle Scholar
  24. (24).
    Seland,T.P., McPherson,T.A.: Evaluation of antithymocyte globulin in acute relapses of multiple sclerosis. Neurology (Minneap.) 24 (1974) 34–40CrossRefGoogle Scholar
  25. (25).
    Siegwald,J. et al.: Etude critiqe du traitment de la sclérose en plaques par le chlorambucil et la corticothérapie intrarachidienne. Rev. Neurol. 129 (1973) 72–77Google Scholar
  26. (26).
    Walker,J.E.: A trial of antilymphocyte globuline in the treatment of chronic progressive multiple sclerosis. J.Neurol. Sci. 29 (1976) 303–309CrossRefGoogle Scholar
  27. (27).
    Weiner,L.P.: Complications of immunosuppressive therapy. In: H.J.Bauer (Ed.): Progress in MS-research. Berlin, Springer, 1980 (in press)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1981

Authors and Affiliations

  • Peter R. Pocklington
    • 1
  • Udo Patzold
    • 2
  1. 1.Department of Medical InformaticsHannover Medical SchoolDeutschland
  2. 2.Department of NeurologyHannover Medical SchoolDeutschland

Personalised recommendations